September 4, 2015
In a retrospective analysis, researchers found that patients with hepatitis C virus infection who achieved sustained virologic response after treatment with an Incivek-based regimen showed improvement in serum markers for liver fibrosis, according to study data.
Data of 1,208 patients with HCV was collected and evaluated from the PROVE3 phase 2 clinical study and the ADVANCE and REALIZE phase 3 clinical studies that were investigating Incivek (telaprevir, Vertex Pharmaceuticals Inc.). For the analysis, all patients were divided according to severity of fibrosis measured through their baseline Metavir score, and whether or not they reached SVR after treatment. The researchers measured the patients’ scores from four biomarker tests: FibroTest, aspartate aminotransferase (AST) to Platelet Ratio Index (APRI), Fibrosis-4 (FIB-4) and Forns' Score, before and after HCV treatment.